Related references
Note: Only part of the references are listed.A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
C-C Lin et al.
BRITISH JOURNAL OF CANCER (2014)
Molecular-targeted agents combination therapy for cancer: Developments and potentials
Feifei Li et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
Joanna M. Brell et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
G. Bousquet et al.
BRITISH JOURNAL OF CANCER (2011)
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
Janine M. Davies et al.
LUNG CANCER (2011)
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Marc S. Ballas et al.
ONCOTARGETS AND THERAPY (2011)
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Isamu Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
XQ Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells
B Spänkuch-Schmitt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Mitotic kinases as regulators of cell division and its checkpoints
EA Nigg
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
